Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, L. A., Lafayette, R., Maes, B., Małecki, R., Mercer, A., Noronha, I. L., Oh, S. W., … Zizzi, C. F. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. The Lancet, 402(10417), 2077–2090. https://doi.org/10.1016/s0140-6736(23)02302-4
Authors:
Brad H Rovin
Jonathan Barratt
Hiddo J L Heerspink
Charles E Alpers
Stewart Bieler
Dong-Wan Chae
Ulysses A Diva
Jürgen Floege
Loreto Gesualdo
Jula K Inrig
Donald E Kohan
Radko Komers
Laura Ann Kooienga
Richard Lafayette
Bart Maes
Robert Małecki
Alex Mercer
Irene L Noronha
Se Won Oh
Chen Au Peh
Manuel Praga
Priscila Preciado
Jai Radhakrishnan
Michelle N Rheault
William E Rote
Sydney C W Tang
Vladimir Tesar
Howard Trachtman
Hernán Trimarchi
James A Tumlin
Muh Geot Wong
Vlado Perkovic
Affiliated Authors:
Jai Radhakrishnan
Columbia Affiliation:
Subjects:
Glomerulonephritis, IGA (MeSH)
Kidney Failure, Chronic (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1016/s0140-6736(23)02302-4
PMID:
37931634
DOI:
10.1016/s0140-6736(23)02302-4
Journal:
Lancet
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: